AMPK/mTOR/ULK1通路激活的自噬参与AURKB介导的神经病理性疼痛中的小胶质细胞增生

Autophagy activated by the AMPK/mTOR/ULK1 pathway involves AURKB-mediated microgliosis in neuropathic pain

作者信息Mu Xu, Zhijian Wang, Zhisheng Wu, Daying Zhang, Xuexue Zhang, Ziqiang Yu, Yi Yan
PMID40721174
发布时间2025-10
DOI10.1016/j.bbi.2025.07.019

实验完整度

包含CCI大鼠模型、原代小胶质细胞、行为学测试、分子检测及功能验证

主要模型

CCI大鼠神经病理性疼痛模型 原代脊髓小胶质细胞

重点核对

CCI手术:四根4-0铬肠线间隔1mm松散结扎左侧坐骨神经 AURKB敲低:鞘内注射AAV-sh-AURKB(10 μL,1×10^12 TU/mL)术前3周 AMPK抑制:Compound C(0.25 μmol/kg,鞘内注射,术后每日) 行为学检测:PWMT(von Frey纤维丝0.4-15g)和PWTL(辐射热) 自噬抑制:3-MA(5 mM)处理原代小胶质细胞

摘要

Background: Neuropathic pain (NP) is linked to microglial activation and neuroinflammation; however, the regulatory mechanisms governing microglial autophagy in NP are not yet fully understood. This study investigates aurora kinase B (AURKB) as a regulator of autophagy and microgliosis through the AMPK/mTOR/ULK1 pathway. Methods: Rats underwent chronic constriction injury (CCI), and spinal microglia were exposed to lipopolysaccharide (LPS) to induce NP models both in vivo and in vitro. AURKB knockdown was achieved using viral vectors carrying AURKB-targeting shRNA. The mRNA expression levels of inflammatory cytokines (IL-1β, IL-6, CCL2) were examined using qPCR and ELISA. Immunofluorescence and Western blotting were employed to assess the levels of Iba1 and p-p38, autophagy markers (LC3, Beclin1, p62), and the activation status of the AMPK/mTOR/ULK1 pathway. Results: CCI and LPS significantly upregulated AURKB in spinal microglia, which was accompanied by dysregulation of autophagy, as evidenced by reduced levels of LC3 and Beclin1, along with elevated levels of p62. AURKB knockdown restored autophagy, resulting from notable increases in AMPK and ULK1 phosphorylation, coupled with a reduction in mTOR phosphorylation. Furthermore, AURKB knockdown reduced microglial activation, as indicated by lower levels of Iba1 and p-p38, and decreased the release of pro-inflammatory cytokines. Importantly, AMPK inhibition partially reversed these protective effects, confirming the role of the AMPK/mTOR/ULK1 pathway in regulating autophagy and microgliosis driven by AURKB. Conclusion: This study identifies AURKB as a novel regulator of autophagy and microgliosis in NP through the AMPK/mTOR/ULK1 pathway, highlighting its potential as a therapeutic target.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
AURKB是否通过AMPK/mTOR/ULK1通路调节自噬从而影响神经病理性疼痛中的小胶质细胞增生?
核心机制
AURKB通过抑制AMPK/mTOR/ULK1通路介导的自噬,促进脊髓小胶质细胞增生和神经病理性疼痛的发展。
主要证据
在CCI大鼠模型和LPS处理的原代小胶质细胞中,AURKB敲低恢复了LC3和Beclin1水平,降低了p62水平,同时上调p-AMPK和p-ULK1并下调p-mTOR,从而减轻小胶质细胞激活和疼痛行为。
研究意义
靶向AURKB可能为治疗神经病理性疼痛提供新的策略,通过恢复自噬来调节神经炎症和小胶质细胞活性。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

建立CCI大鼠模型并验证疼痛行为

确认神经病理性疼痛模型建立成功

对SD大鼠进行CCI手术,通过von Frey filaments检测机械性痛觉超敏和热痛觉过敏,评估疼痛行为。

2

检测AURKB表达和自噬水平变化

确定AURKB在神经病理性疼痛中的表达变化及自噬状态

通过qPCR和Western blot检测脊髓组织中AURKB和自噬标记物LC3、Beclin1、p62的表达;通过免疫荧光检测AURKB与Iba1共定位。

3

LPS诱导小胶质细胞激活并敲低AURKB

验证AURKB敲低对小胶质细胞激活和自噬的影响

原代小胶质细胞用LPS激活,并用Lv-sh-AURKB敲低AURKB,检测自噬标记物、炎症因子表达及小胶质细胞激活标志物p-p38。

4

验证AMPK/mTOR/ULK1通路参与

确定AURKB调节自噬是否依赖AMPK/mTOR/ULK1通路

检测AMPK、mTOR、ULK1磷酸化水平,并通过敲低AMPK或使用Compound C抑制AMPK,观察对AURKB敲低效应的影响。

5

体内验证AURKB敲低对自噬和疼痛行为的影响

在动物水平确认AURKB敲低通过AMPK/mTOR/ULK1通路缓解神经病理性疼痛

CCI大鼠鞘内注射AAV-sh-AURKB敲低AURKB,并用Compound C抑制AMPK,检测疼痛行为、脊髓小胶质细胞增生和炎症因子水平。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

产品清单

实验环节名称品牌货号
Sprague-Dawley大鼠Hunan SJA Laboratory Animal Co., Ltd.--
异氟烷----
利多卡因----
4-0铬肠线----
腺相关病毒9型HANBIO--
Compound CMedChemExpressHY13418A
Von Frey纤维丝----
DMEM培养基Thermo Fisher Scientific--
胎牛血清Gibco--
青霉素-链霉素Gibco--
谷氨酰胺Gibco--
0.25%胰酶-EDTAThermo Fisher Scientific--
脂多糖Sigma-Aldrich--
3-甲基腺嘌呤Sigma-Aldrich--
聚凝胺----
TRIzol试剂Invitrogen--
PrimeScript逆转录试剂盒Takara--
SYBR Green预混液Applied Biosystems--
ABI 7500实时荧光定量PCR仪Applied Biosystems--
RIPA裂解液Beyotime--
PVDF膜Merck Millipore--
AURKB抗体Abcamab2254
LC3抗体Abcamab192890
Beclin1抗体Abcamab207612
p62抗体Abcamab240635
AMPK抗体Abcamab32047
磷酸化AMPK抗体Cell Signaling Technology2531
mTOR抗体Abcamab32028
磷酸化mTOR抗体Cell Signaling Technology5536
ULK1抗体Cell Signaling Technology8054
磷酸化ULK1抗体Abcamab203207
β-微管蛋白抗体Abcamab6046
β-肌动蛋白抗体Abcamab8227
HRP标记二抗Abcamab6721
增强化学发光试剂盒Thermo Fisher Scientific--
牛血清白蛋白Sigma-Aldrich--
Iba1抗体Abcamab178847
磷酸化p38抗体Cell Signaling Technology4511
Alexa 488标记二抗Abcamab150077
Alexa 594标记二抗Abcamab150080
DAPISigma-Aldrich--
荧光显微镜Leica--
IL-1β ELISA试剂盒ElabscienceE-EL-R0012
IL-6 ELISA试剂盒ElabscienceE-EL-R0015
CCL2 ELISA试剂盒ElabscienceE-EL-R0633
酶标仪BioTek--
GraphPad Prism 8.0GraphPad Software--

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
动物模型
CCI手术细节:四根4-0铬肠线间隔1mm结扎坐骨神经;手术时间点;动物品系、性别、周龄、体重
阅读提示:Material and methods: Experimental animals, NP model
细胞实验
原代脊髓小胶质细胞分离和培养条件;LPS处理浓度和时间;慢病毒感染MOI和时间;3-MA处理浓度和时间
阅读提示:Material and methods: Spinal microglia isolation and culture, Cell treatment
分子检测
抗体稀释比例;蛋白上样量;qPCR引物序列和反应条件;ELISA操作步骤
阅读提示:Material and methods: Western blot analysis, qPCR assay, ELISA
行为学检测
PWMT和PWTL测试具体操作;von Frey filament力度范围和测试次数
阅读提示:Material and methods: Behavioral assessment